DE-ZAPI-GROUP
19.3.2024 14:01:31 CET | Business Wire | Press release
ZAPI GROUP, a global leader in electrification, announced today it is showcasing its solutions for the material handling and electrification industries at LogiMAT 2024. At the event, ZAPI GROUP is announcing the expansion of BlueBotics, a ZAPI GROUP company and leader in autonomous navigation technology. BlueBotics has partnered with Pramac, a leading global supplier of warehouse material handling equipment, and expanded its ANT server mission and fleet management software. These milestones bolster ZAPI GROUP's standing as a comprehensive autonomous navigation and AGV fleet management provider for electrification.
"The expansion of BlueBotics is an exciting milestone as ZAPI GROUP continues to grow its capabilities to serve the global AGV and material handling sectors," noted Lloyd Gomm, Global Marketing Director at ZAPI GROUP. "BlueBotics’ consistent innovation in navigation software enables the company to broaden the spectrum of solutions and integrated systems available to our OEM customers. LogiMAT presents an opportunity to showcase these developments and other product innovations with the industry.”
The ZAPI GROUP is exhibiting at LogiMAT 2024 in Stuttgart from March 19 - 21 in hall 6, booth 6C61. They provide a wide array of capabilities for OEMs with a range of electrification and automation solutions for material handling machines and robots, including inverters and controllers, electric motors, high-frequency battery chargers and accessories. Its companies leading innovation across AGV and material handling sectors include BlueBotics, Zapi, Inmotion Technologies, Delta-Q Technologies, Zivan, Schabmüller, 4E Consulting, Best Motor and ZTP.
At the ZAPI GROUP booth at LogiMAT, the BlueBotics team is announcing the agility of its ANT server fleet management software to control not only more than 100 “ANT driven” customer vehicles but also now VDA 5050-compliant AGVs and AMRs. The company will also demo Pramac’s X-ACT HYBRIX robot, a new line of X-ACT mobile logistics robots powered by BlueBotics’ latest version of its software, as part of its on-stand multi-brand AGV/AMR fleet demo.
“We are thrilled to further expand our suite of autonomous navigation and AGV fleet management solutions,” said BlueBotics’ CEO, Dr. Nicola Tomatis. “BlueBotics has a proven track record of developing autonomous solutions for a variety of mobile robotic platforms. These solutions continue to complement ZAPI GROUP's existing system integration capabilities, advance its electrification mission and enhance OEMs’ access to robust solutions for material handling automation.”
The ZAPI GROUP recently hosted industry leaders at its annual virtual conference, The Future of Electrification. This was the company’s third year hosting the event aimed to drive education and innovations for electrification across its key industries.
To learn more about ZAPI GROUP and its companies, visit them at LogiMAT 2024 (hall 6, stand 6C61).
About ZAPI GROUP
ZAPI GROUP is engineering the transition to an all-electric future with a highly integrated product portfolio, including motion controllers, electric motors, high-frequency battery chargers, and autonomous navigation software for application in full-electric and hybrid vehicles. As a global electrification leader with deep systems experience, leading innovations, and an obsession with driving customers' success, ZAPI GROUP now counts more than 1700 employees worldwide with total annual revenue of more than 700 million US dollars.
For more information about the group, visit www.zapigroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240319748003/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom